MDXXF Stock Chart & Stats
$0.16
<$0.01(6.31%)
At close: 4:00 PM EDT
$0.16
<$0.01(6.31%)
Day’s Range― - ―
52-Week Range$0.06 - $0.24
Previous CloseN/A
Volume100.00
Average Volume (3M)29.07K
Market Cap
$12.48M
Enterprise Value$18.29M
Total Cash (Recent Filing)$245.06K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding109,236,030
10 Day Avg. Volume4,425
30 Day Avg. Volume29,073
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue14.43
Enterprise Value/Gross Profit-58.91
Enterprise Value/Ebitda-12.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth shows that PharmAla is gaining commercial traction and increasing demand for its regulated products. If this expansion continues, greater scale could improve operating leverage, support reinvestment in the business, and strengthen its position in clinical and research supply markets.
Debt-Free Balance SheetThe absence of reported debt gives PharmAla greater financial flexibility than a similarly loss-making company carrying substantial leverage. With no meaningful interest burden or debt refinancing obligation, more future capital can be directed toward operations, product development, and commercial expansion.
Positive Equity And Asset BasePositive equity and a meaningful asset base provide some support for the company while it remains early stage. This foundation may help sustain regulated production and development activities, and offers greater resilience than a balance sheet already impaired by negative equity.
Bears Say
Persistent Operating LossesNegative gross profit and deeply negative operating earnings indicate that current revenue does not yet cover the cost structure. Without material improvement in pricing, product mix, or operating efficiency, revenue growth may continue to require external funding rather than translate into durable profitability.
Negative Cash GenerationCash burn of roughly $0.97 million over the trailing period means operations are consuming capital rather than self-funding growth. Continued negative free cash flow can constrain investment capacity and make financing needs persistent unless revenue scales materially or operating costs decline.
Negative Returns And Erosion RiskA deeply negative return on equity shows that the existing capital base is not yet producing profitable returns. If losses persist, the company may erode equity or depend on additional capital, potentially increasing dilution and limiting the resources available for long-term growth.
PharmAla Biotech Holdings, Inc. News
MDXXF FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was $0.06 and its highest was $0.24 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is $12.48M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Dec 18, 2026 which is in 54 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Jul 29, 2026. The company reported -$0.004 earnings per share for the quarter.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 109,236,030 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -$0.004 in its last earnings report. Following the earnings report the stock price went down -0.893%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in MDXXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.